Address Nirmatrelvir/Ritonavir (Paxlovid) Interactions

You can help answer questions when patients with COVID-19 taking nirmatrelvir/ritonavir (Paxlovid) present to the hospital.

It’s too soon to say if patients taking nirmatrelvir/ritonavir should continue it on admission. It’s okay to complete the course...but you’ll likely need to use a patient’s home supply.

Be ready to manage interactions...since the ritonavir component is a strong CYP3A4 and P-glycoprotein inhibitor.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote